Cogstate Ltd FY26 Results: Revenue and Profit Growth
Key points
- Total revenue increased by 14.6% to $60.9m
- Clinical Trials revenue increased by 15.4% to $58.4m
- Profit before tax increased by 15.9% to $16.1m
- Fully franked final dividend of A$0.04 per share declared
Full summary
Cogstate Ltd reported a strong financial performance for the year ended 30 June 2026, with total revenue from ordinary activities increasing by 14.6% to $60.86 million. Clinical Trials revenue, which accounts for the majority of the company's revenue, saw a significant 15.4% increase to $58.4 million. The company also reported a 15.9% increase in profit before income tax to $16.1 million. The company declared a fully franked final dividend of A$0.04 per share, totaling A$6.8 million.
Guidance
FY26 revenue: $60.86 million, profit before tax: $16.1 million, dividend: A$0.04 per share
Outlook
Cogstate Ltd anticipates continued growth in clinical trials revenue and overall profitability in the coming years.
Summary generated by a large language model. Please interpret with care.